A Multicenter Trial Assessing the Efficacy and Safety of tamOxifen Plus LY2228820 in Advanced or Metastatic Breast Cancer Progressing on aromatasE Inhibitors (OLYMPE)

A Randomized Open-label Phase II Multicenter Trial Assessing the Efficacy and Safety of tamOxifen Plus LY2228820 in Advanced or Metastatic Breast Cancer Progressing on aromatasE Inhibitors

Metastatic breast cancer (MBC) remains an incurable disease and despite an improvement of the effect of systemic treatments. After relapse on first-line non-steroidal aromatase inhibitor, current clinical practice and treatment guidelines include tamoxifen, fulvestrant (an ER antagonist) and exemestane as available options (NCCN treatment guidelines 2012), but in this context of resistance, their efficacy are poor.

Some results confirm the possibility to improve the efficacy of tamoxifen in metastatic setting by a combination with therapy targeting signal transduction pathways. Other transduction pathways seem to be involved in endocrine sensitivity/resistance, such as RAS/RAF/MEK/MAK pathway.

LY2228820 inhibits the activity of p38 MAPK (selective inhibitor of the α and β isoforms of p38 MAPK in vitro) and reduces phosphorylation of its cellular target, MAPK-activated protein kinase 2 (MAPKAP-K2).

Study Overview

• Status: Terminated
• Conditions: Metastatic Breast Cancer; Postmenopausal
• Intervention / Treatment: Drug: Tamoxifen; Drug: Ralimetinib (LY2228820 dimesylate)

• Study Type: Interventional
• Enrollment (Actual): 8
• Phase: Phase 2

Contacts and Locations

Study Locations

• France
  • Bordeaux, France
    • Institut Bergonie
  • Caen, France
    • Centre Francois Baclesse
  • Clermont -Ferrand, France
    • Centre Jean Perrin
  • Dijon, France
    • Centre Georges-Francois Leclerc
  • Lyon, France
    • Centre Leon Berard
  • Marseille, France
    • Institut Paoli Calmettes
  • Nantes, France
    • Institut de Cancérologie de l'Ouest
  • Paris, France
    • Hegp, Ap-Hp
  • Paris, France
    • Hôpital St Louis, AP-HP
  • Rennes, France
    • Centre Eugène Marquis
  • Rouen, France
    • Centre Henri Becquerel
  • St Cloud, France
    • Institut Curie
  • Toulouse, France
    • Institut Claudius Regaud
  • Villejuif, France
    • Institut Gustave Roussy

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• Women with histologically confirmed breast cancer
• 18 < age < 80 years old

• Menopausal status Women are considered post-menopausal and not of child bearing potential if they have had

  • 12 months of spontaneous amenorrhea with an appropriate clinical profile (e.g., age appropriate, history of vasomotor symptoms) or
  • 6 months of spontaneous amenorrhea with serum FSH levels > 40 mIU/mL and estradiol < 20 pg/mL or
  • surgical bilateral oophorectomy (with or without hysterectomy) at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential
• ER-positive status by local laboratory testing (>10% by IHC) and HER2-negative status (IHC 0 or 1+ or 2+ and FISH negative) on the last biopsy or surgical specimen available.
• Disease progression defined as inoperable locally advanced or metastatic breast cancer (MBC) excluding aggressive visceral disease requiring other approaches, such as chemotherapy

• Disease refractory to aromatase inhibitors (AI) defined as:

  • recurrence while on, or within 12 months of end of adjuvant treatment with aromatase inhibitor, or
  • progression while on, or within 3 months of end of AI for locally advanced or MBC
• Patients who have received fulvestrant are eligible
• Maximum 2 previous lines of chemotherapy for MBC
• Performance Status (PS) ≤ 2
• Patient able to swallow and retain oral medication

• Measurable or evaluable lesions as per RECIST 1.1

  • Measurable disease (≥ 20 mm by conventional techniques or ≥ 10 mm by spiral computed tomography scan) or
  • Non-measurable lytic or mixed (lytic + blastic) bone lesions in the absence of measurable disease.
  • Patients with only pleural effusion and/or ascites are not eligible.

• Adequate bone marrow and organ function as defined by the following laboratory values:

  • Absolute Neutrophil Count (ANC) ≥ 1.0 x 109/L
  • Platelets (plt) ≥ 100 x 109/L
  • Hemoglobin (Hgb) ≥ 9 g/dl
  • INR ≤ 1.5 without any anticoagulation treatment
  • Serum creatinine ≤ 1.5 x ULN
  • Alanine aminotransferase (AST) and aspartate aminotransferase (ALT) within normal range (or < 3.0 x ULN if liver metastases are present)
  • Total serum bilirubin within normal range (or ≤ 1.5 x ULN if liver metastases are present; or total bilirubin ≤ 3.0 x ULN with direct bilirubin within normal range in patients with well documented Gilbert's Syndrome, which is defined as presence of several episodes of unconjugated hyperbilirubinemia with normal results from CBC count (including normal reticulocyte count and blood smear), normal liver function test results, and absence of other contributing disease processes at the time of diagnosis
• Patient has signed informed consents obtained before any trial related activities and according to local guidelines

Exclusion Criteria:

• • Previous treatment with p38 MAPK inhibitors or Tamoxifen in metastatic setting (adjuvant treatment by tamoxifen is allowed)

  • More than 2 lines of chemotherapy for locally advanced and/or metastatic breast cancer
  • Brain metastasis
  • Other malignancy (with the exception of adequately treated, basal or squamous cell carcinoma, non-melanomatous skin cancer or curatively resected cervical cancer).
  • Clinically significant (i.e. active) cardiovascular disease: cerebro-vascular accident/stroke or myocardial infarction within 6 months prior to first study medication; unstable angina; CHF of New York Heart Association (NYHA) Grade II or higher; or serious cardiac arrhythmia requiring medication.
  • Have had a major bowel resection that would alter oral drug absorption.
  • Have a diagnosis of inflammatory bowel disease (Crohn's disease or ulcerative colitis).
  • Are receiving concurrent administration of immunosuppressive therapy
  • Concurrent participation in any therapeutic clinical trial
  • Assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: TAMOXIFEN; Tamoxifen will be administered daily orally Patients will receive study medication until disease progression or unacceptable toxicity	Drug: Tamoxifen; hormonotherapy
Experimental: TAMOXIFEN + LY2228820; Tamoxifen will be administered daily orally LY2228820 dimesylate (Ralimetinib) will be administered orally Patients will receive study medication until disease progression or unacceptable toxicity	Drug: Tamoxifen; hormonotherapy; Drug: Ralimetinib (LY2228820 dimesylate); Other Names: target therapy

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
To define the efficacy (progression-free survival rate at 6 months) of LY2228820 in combination with tamoxifen for postmenopausal women with an ER positive and HER2 negative advanced or metastatic breast cancer who progressed on aromatase inhibitors.	at 6 months after treatment start.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
- To evaluate the toxicity profile (Safety and Tolerability) of the LY2228820 in combination with tamoxifen	Adverse events description and grade in all participants	From date of randomization until study participation (during average 12 months)
- To estimate the Progression-Free Survival of the LY2228820 in combination with tamoxifen		evaluated every 8-12 weeks (during average 12 months)
- To assess the overall survival of the LY2228820 in combination with tamoxifen		From date of randomization until the date of first documented date of death from any cause, whichever came first, assessed up to 60 months
- To assess response duration of the LY2228820 in combination with tamoxifen		evaluated every 8-12 weeks during treatment to progression or death for any cause.(during average 12 months)

Collaborators and Investigators

• Sponsor: Centre Francois Baclesse
• Collaborators: National Cancer Institute, France; ARC Foundation for Cancer Research
• Investigators: Principal Investigator: Christelle LEVY, MD, c.levy@baclesse.unicancer.fr

Study record dates

Study Major Dates

• Study Start (Actual): January 1, 2015
• Primary Completion (Actual): April 1, 2017
• Study Completion (Actual): April 1, 2017

Study Registration Dates

• First Submitted: December 12, 2014
• First Submitted That Met QC Criteria: December 22, 2014
• First Posted (Estimate): December 23, 2014

Study Record Updates

• Last Update Posted (Actual): May 24, 2017
• Last Update Submitted That Met QC Criteria: May 23, 2017
• Last Verified: May 1, 2017

More Information

Terms related to this study

• Keywords: Metastatic breast cancer; tamoxifen; p38 map kinase; LY2228820; Postmenopausal woman with advanced or metastatic breast cancer progressing on aromatase inhibitors (AI)
• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms; Neoplasms by Site; Breast Diseases; Breast Neoplasms; Physiological Effects of Drugs; Antineoplastic Agents; Hormones, Hormone Substitutes, and Hormone Antagonists; Antineoplastic Agents, Hormonal; Hormone Antagonists; Bone Density Conservation Agents; Estrogen Antagonists; Selective Estrogen Receptor Modulators; Estrogen Receptor Modulators; Tamoxifen
• Other Study ID Numbers: OLYMPE / 2013-005084-29